Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Stem Cell Therapy for Tissue Regeneration

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Treating Castleman disease: insights into the use and efficacy of monoclonal antibodies.

Expert opinion on biological therapy·2026

Same author

Idecabtagene vicleucel and endogenous T-cell phenotypes linked to progression-free survival in relapsed multiple myeloma.

HemaSphere·2026

Same author

Real-World Outcomes with BCMA- and GPRC5D-Targeting Bispecific Antibodies in Plasma Cell Leukemia.

Blood advances·2026

Same author

Arlocabtagene autoleucel-a GPRC5D-targeted CAR T-cell therapy in heavily pretreated relapsed/refractory multiple myeloma.

Blood·2026

Same author

Treatment of Multiple Myeloma: ASCO Living Guideline, Version 2026.1.1.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same author

Collection of autologous CD34+ hematopoietic progenitor cells (HPC) in multiple myeloma: CD34 + cell collection yield in relation to molecular subtype, karyotype, and FISH results.

PloS one·2026

Search research articles

Related Experiment Video

Updated: May 3, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

How I Treat Plasma Cell Leukemia.

Samer Al Hadidi¹, Frits van Rhee², Larry D Anderson³

¹UT Southwestern Medical Center, Dallas, Texas, United States.

|May 1, 2026

Summary

This summary is machine-generated.

Plasma cell leukemia (PCL) is an aggressive cancer. Novel therapies show promise, but more research is needed to improve outcomes for this rare disease.

More Related Videos

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

Modeling Chemotherapy Resistant Leukemia In Vitro

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

Related Experiment Videos

Last Updated: May 3, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

Modeling Chemotherapy Resistant Leukemia In Vitro

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

Area of Science:

Hematology
Oncology
Molecular Biology

Background:

Plasma cell leukemia (PCL) is a rare and aggressive plasma cell malignancy.
It is defined by ≥5% circulating plasma cells in peripheral blood and associated with high-risk features.

Purpose of the Study:

To review current evidence and clinical approaches for PCL.
To highlight knowledge gaps and the need for dedicated clinical trials.

Main Methods:

Literature review of current evidence on PCL.
Synthesis of data from multiple myeloma (MM) trials and novel therapeutic studies.
Presentation of illustrative clinical cases.

Main Results:

PCL exhibits distinct clinical and molecular features, including extramedullary involvement and high-risk cytogenetics.
Novel therapies like BCMA-directed treatments, GPRC5D-targeted therapy, and BCL-2 inhibition show promise.
Current treatment strategies are often extrapolated from MM, with PCL patients largely excluded from trials.

Conclusions:

Despite advances, PCL remains inadequately studied.
Dedicated prospective clinical trials are crucial to improve outcomes for PCL patients.
Novel therapeutic strategies offer hope but require further investigation in dedicated PCL studies.